Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical group developing new therapies and treatments for deadly blood diseases - Submits investigational new drug application seeking authorisation from the US Food & Drug Administration to begin a phase 1 clinical trial of its lead product chemic antigen receptor T-cells, or Hemo-Car-T, for treating acute myeloid leukemia.

Says the application follows ‘successful work on manufacturability, quality, safety and other key parts’ of developing Hemo-Car-T. Says it plans to initiate a phase 1 clinical trial of Hemo-Car-T, once the clinical investigation plan proposed in the IND submission has been cleared to proceed by the FDA.

Co-Founder & Chief Executive Officer Vladislav Sandler says: ‘We are pleased to have reached this milestone with Hemo-Car-T. We are committed to advancing therapies for blood diseases, and our work to address [acute myeloid leukemia], which currently has poor survival rates, is an essential part of that commitment.’

Current stock price: 2.10 pence, up 4.0%

12-month change: up 54%

Copyright 2023 Alliance News Ltd. All Rights Reserved.